Total Payments
$262,029
2021 Payments
$11,017
Companies
29
Transactions
272
Medicare Patients
422
Medicare Billing
$109,971
Payment Breakdown by Category
Consulting$148,965 (56.9%)
Travel$52,142 (19.9%)
Other$43,470 (16.6%)
Research$9,251 (3.5%)
Food & Beverage$8,192 (3.1%)
Education$9.75 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $148,965 | 41 | 56.9% |
| Travel and Lodging | $52,142 | 82 | 19.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $37,470 | 11 | 14.3% |
| Unspecified | $9,251 | 6 | 3.5% |
| Food and Beverage | $8,192 | 127 | 3.1% |
| Honoraria | $4,500 | 1 | 1.7% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $1,500 | 3 | 0.6% |
| Education | $9.75 | 1 | 0.0% |
Payments by Type
General
$252,779
266 transactions
Research
$9,251
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $61,054 | 86 | $0 (2020) |
| Merck Sharp & Dohme Corporation | $40,853 | 26 | $0 (2020) |
| F. Hoffmann-La Roche AG | $18,740 | 16 | $0 (2019) |
| Ferring Pharmaceuticals Inc. | $16,961 | 12 | $0 (2019) |
| Bayer HealthCare Pharmaceuticals Inc. | $16,364 | 12 | $0 (2019) |
| SANOFI US SERVICES INC. | $11,836 | 10 | $0 (2020) |
| Janssen Global Services, LLC | $10,853 | 5 | $0 (2019) |
| GENZYME CORPORATION | $10,275 | 17 | $0 (2019) |
| Genentech USA, Inc. | $10,252 | 6 | $0 (2018) |
| PFIZER INC. | $9,858 | 10 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $11,017 | 5 | MacroGenics, Inc. ($6,683) |
| 2020 | $19,488 | 25 | E.R. Squibb & Sons, L.L.C. ($10,650) |
| 2019 | $110,183 | 115 | Merck Sharp & Dohme Corporation ($36,007) |
| 2018 | $58,964 | 58 | E.R. Squibb & Sons, L.L.C. ($19,967) |
| 2017 | $62,378 | 69 | F. Hoffmann-La Roche AG ($15,630) |
All Payment Transactions
272 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/21/2021 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $1,860.00 | Research |
| 04/21/2021 | MacroGenics, Inc. | — | — | Cash or cash equivalent | $6,683.22 | Research |
| Study: FLOTETUZUMAB IN PRIMARY INDUCTION FAILURE PIF OR EARLY RELAPSE ER ACUTE MYELOID LEUKEMIA AML | ||||||
| 01/04/2021 | SANOFI-AVENTIS U.S. LLC | — | Consulting Fee | Cash or cash equivalent | $1,060.00 | General |
| 01/04/2021 | SANOFI-AVENTIS U.S. LLC | — | Consulting Fee | Cash or cash equivalent | $707.00 | General |
| 01/04/2021 | SANOFI-AVENTIS U.S. LLC | — | Consulting Fee | Cash or cash equivalent | $707.00 | General |
| 05/28/2020 | SANOFI US SERVICES INC. | — | Consulting Fee | Cash or cash equivalent | $2,695.50 | General |
| 05/27/2020 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $489.83 | Research |
| Study: A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER | ||||||
| 05/13/2020 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| 03/31/2020 | E.R. Squibb & Sons, L.L.C. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,125.00 | General |
| 03/27/2020 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $52.80 | Research |
| Study: A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER | ||||||
| 03/06/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $322.38 | General |
| Category: ONCOLOGY | ||||||
| 03/06/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $279.80 | General |
| Category: ONCOLOGY | ||||||
| 03/06/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $65.00 | General |
| Category: ONCOLOGY | ||||||
| 03/06/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $60.00 | General |
| Category: ONCOLOGY | ||||||
| 03/05/2020 | E.R. Squibb & Sons, L.L.C. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,125.00 | General |
| 03/04/2020 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $898.73 | General |
| 03/04/2020 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $763.42 | General |
| 03/04/2020 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $52.63 | General |
| 02/27/2020 | Janssen Research & Development, LLC | — | Food and Beverage | In-kind items and services | $19.11 | General |
| 02/26/2020 | Janssen Research & Development, LLC | — | Travel and Lodging | In-kind items and services | $155.68 | General |
| 02/25/2020 | Janssen Research & Development, LLC | — | Travel and Lodging | In-kind items and services | $173.40 | General |
| 02/25/2020 | Janssen Research & Development, LLC | — | Travel and Lodging | In-kind items and services | $113.64 | General |
| 02/19/2020 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $416.98 | General |
| 02/19/2020 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $148.00 | General |
| 02/19/2020 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $120.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| FLOTETUZUMAB IN PRIMARY INDUCTION FAILURE PIF OR EARLY RELAPSE ER ACUTE MYELOID LEUKEMIA AML | MacroGenics, Inc. | $6,683 | 1 |
| A PHASE 1/2 STUDY OF REGN5678 (ANTI-PSMAXCD28) WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER | Regeneron Pharmaceuticals, Inc. | $542.63 | 2 |
| A Phase 1 2a Study of BMS 986253 in Combination with Nivolumab in Advanced Cancers | E.R. Squibb & Sons, L.L.C. | $95.00 | 1 |
| An Investigational Immunotherapy Study of BMS 986249 Alone and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread | E.R. Squibb & Sons, L.L.C. | $70.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 68 | 130 | $63,050 | $12,675 |
| 2022 | 2 | 68 | 166 | $74,930 | $15,152 |
| 2021 | 3 | 86 | 304 | $101,960 | $30,811 |
| 2020 | 4 | 200 | 483 | $161,760 | $51,333 |
Total Patients
422
Total Services
1,083
Medicare Billing
$109,971
Procedure Codes
12
All Medicare Procedures & Services
12 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 33 | 73 | $38,690 | $8,005 | 20.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 23 | 39 | $14,820 | $3,108 | 21.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 12 | 18 | $9,540 | $1,562 | 16.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 34 | 79 | $41,870 | $8,897 | 21.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 34 | 87 | $33,060 | $6,255 | 18.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 53 | 176 | $59,120 | $12,993 | 22.0% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2021 | 11 | 60 | $9,600 | $9,734 | 101.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 22 | 68 | $33,240 | $8,084 | 24.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 87 | 210 | $90,300 | $20,319 | 22.5% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2020 | 26 | 120 | $19,200 | $19,043 | 99.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 75 | 141 | $42,300 | $9,739 | 23.0% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 12 | 12 | $9,960 | $2,232 | 22.4% |
About Dr. Charles Drake, M.D
Dr. Charles Drake, M.D is a Hematology & Oncology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1346297397.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Charles Drake, M.D has received a total of $262,029 in payments from pharmaceutical and medical device companies, with $11,017 received in 2021. These payments were reported across 272 transactions from 29 companies. The most common payment nature is "Consulting Fee" ($148,965).
As a Medicare-enrolled provider, Drake has provided services to 422 Medicare beneficiaries, totaling 1,083 services with total Medicare billing of $109,971. Data is available for 4 years (2020–2023), covering 12 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology
- Location New York, NY
- Active Since 05/27/2006
- Last Updated 02/08/2017
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1346297397
Products in Payments
- TECENTRIQ (Biological) $19,569
- Non-Covered Product (Drug) $15,553
- NO PRODUCT DISCUSSED (Drug) $10,378
- JEVTANA (Drug) $9,507
- Non-Covered (Drug) $7,127
- INLYTA (Drug) $5,571
- ELIGARD (Drug) $5,015
- PROVENGE (Drug) $3,375
- REMICADE (Biological) $2,330
- Erleada (Drug) $2,184
- BAVENCIO (Drug) $1,890
- KEYTRUDA (Biological) $727.18
- XTANDI (Drug) $150.03
- ERLEADA (Drug) $91.50
- LIBTAYO (Drug) $75.00
- Xtandi (Drug) $59.45
- FIRMAGON (Drug) $34.74
- Idhifa (Drug) $33.99
- Aliqopa (Drug) $32.47
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in New York
Jeffrey Zwicker, M.d, M.D
Hematology & Oncology — Payments: $1.2M
Hematology & Oncology $1.2M
Manuel Hidalgo Medina, M.d, M.D
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Ahmed Sawas, M.d, M.D
Hematology & Oncology — Payments: $807,524
Hematology & Oncology $807,524
Ruben Niesvizky, Md, MD
Hematology & Oncology — Payments: $734,512
Hematology & Oncology $734,512
Jeffrey Laurence, Md, MD
Hematology & Oncology — Payments: $706,018
Hematology & Oncology $706,018
Dr. Joshua Sabari, M.d, M.D
Hematology & Oncology — Payments: $603,205
Hematology & Oncology $603,205